SCHEMBL20127181

SCHEMBL20127181

c1ccc(-c2nc(-c3ccc(C4(c5ccccc5)c5ccccc5-c5c4ccc4ccccc54)cc3)nc(-c3ccccc3-c3ccccc3)n2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
KDM4E B2RXH2 3/20 0.36
LMNA P02545 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
OPRK1 P41145 1/20 0.36
TSHR P16473 2/20 0.34
ATM Q13315 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
TP53 P04637 1/20 0.34
NFKB1 P19838 1/20 0.34
MAPK1 P28482 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18818836 1.00 MAPT (0.36) MAPTSMN1; SMN2KDM4ELMNAMEN1
SCHEMBL18818846 0.99 MAPT (0.35) MAPTSMN1; SMN2KDM4ELMNAMEN1
SCHEMBL22639481 0.96 MAPT (0.33) MAPTSMN1; SMN2KDM4ELMNAMEN1
SCHEMBL20127170 0.95 MAPT (0.40) MAPTSMN1; SMN2KDM4ELMNAMEN1
SCHEMBL21394016 0.94 MAPT (0.39) MAPTSMN1; SMN2KDM4ELMNAMEN1
SCHEMBL21394019 0.94 MAPT (0.39) MAPTSMN1; SMN2KDM4ELMNAMEN1
SCHEMBL21394113 0.94 MAPT (0.39) MAPTSMN1; SMN2KDM4ELMNAMEN1
SCHEMBL20127193 0.94 MAPT (0.39) MAPTSMN1; SMN2KDM4ELMNAMEN1
SCHEMBL21394241 0.94 MAPT (0.39) MAPTSMN1; SMN2KDM4ELMNAMEN1
SCHEMBL21394116 0.94 MAPT (0.39) MAPTSMN1; SMN2KDM4ELMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10745362-B2 Heterocyclic compound and organic light emitting device comprising same LG CHEM, LTD. (KR) 2020-08-18 US disclosed
US-20180127385-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME LG CHEM LTD. (KR) 2018-05-10 US disclosed
US-20180127385-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME LG CHEM LTD. (KR) 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10745362-B2 Heterocyclic compound and organic light emitting device comprising same CRY1, CRY2, PER2 MAPT 1073/4885SMN1; SMN2 4089/4885KDM4E 2502/4885
US-20180127385-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME CRY1, CRY2, PER2 MAPT 1073/4885SMN1; SMN2 4089/4885KDM4E 2502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.